TNF
The Global Evolution of IBD; Withdrawing Anti-TNF Therapy for IBD in Remission
This month's Regueiro Report looks at one of the most important papers about the epidemiology of IBD to appear for ...
JULY 17, 2025
AGA Issues Updated Guideline on Preventing HBV Reactivation
The AGA has issued an updated clinical practice guideline on prevention and management of HBV reactivation in ...
APRIL 14, 2025
Non–Anti-TNF Agents Safe as 1st-Line Rx Before Anti-TNFs
Treatment with vedolizumab or ustekinumab in CD, or vedolizumab in UC, followed by an anti–TNF was found to ...
JANUARY 3, 2025
Tulisokibart May Be a Promising Treatment For Ulcerative Colitis
Tulisokibart yielded significant and clinically meaningful differences from placebo in UC clinical remission during ...
DECEMBER 30, 2024
Approach to Older Adults With Moderate To Severe Crohn’s Disease
The incidence and prevalence of inflammatory bowel disease are rising worldwide, particularly in older adults.
DECEMBER 23, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 29, 2023
Managing and Maintaining Clinical Response in Moderately to Severely Active Crohn’s Disease: Efficacy and Safety of CIMZIA® (Certolizumab Pegol)
The increase in treatment options has been an important advance for the goal of achieving a sustained remission in ...
APRIL 14, 2023
The Regueiro Report: Optimizing Anti-TNF Treatment for IBD
This month, I’m focusing on how to optimize anti-TNF treatment decisions.
MARCH 31, 2022
Study Finds No Surgical Infection Risk From TNF Inhibitors
San Diego—Patients undergoing surgery with detectable levels of a tumor necrosis factor (TNF) inhibitor are ...
NOVEMBER 6, 2019
